Analysts Expect Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Will Announce Quarterly Sales of $10.15 Million
Brokerages expect that Five Prime Therapeutics, Inc. (NASDAQ:FPRX) will announce $10.15 million in sales for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Five Prime Therapeutics’ earnings. The highest sales estimate is $10.20 million and the lowest is $10.10 million. Five Prime Therapeutics posted sales of $9.23 million in the same quarter last year, which would indicate a positive year over year growth rate of 10%. The firm is scheduled to report its next earnings report after the market closes on Tuesday, August 8th.
On average, analysts expect that Five Prime Therapeutics will report full-year sales of $10.15 million for the current fiscal year, with estimates ranging from $40.50 million to $55.00 million. For the next fiscal year, analysts anticipate that the business will report sales of $25.67 million per share, with estimates ranging from $20.00 million to $30.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Five Prime Therapeutics.
Five Prime Therapeutics (NASDAQ:FPRX) last announced its earnings results on Thursday, May 4th. The biotechnology company reported ($1.21) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.96) by $0.25. The company had revenue of $10.13 million for the quarter, compared to analysts’ expectations of $6.05 million. Five Prime Therapeutics had a negative return on equity of 21.81% and a negative net margin of 250.98%. The company’s quarterly revenue was up 55.8% compared to the same quarter last year. During the same period last year, the business earned ($0.49) EPS.
FPRX has been the subject of a number of recent research reports. Zacks Investment Research downgraded Five Prime Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, May 2nd. Jefferies Group LLC reaffirmed a “buy” rating and set a $55.00 price objective on shares of Five Prime Therapeutics in a research note on Friday, May 5th. ValuEngine raised Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Finally, BidaskClub cut Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 2nd. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $60.83.
Shares of Five Prime Therapeutics (NASDAQ FPRX) opened at 29.43 on Monday. The company has a 50-day moving average of $29.82 and a 200 day moving average of $35.52. Five Prime Therapeutics has a one year low of $26.65 and a one year high of $60.98. The firm’s market cap is $821.01 million.
TRADEMARK VIOLATION WARNING: This report was first published by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2017/08/07/analysts-expect-five-prime-therapeutics-inc-nasdaqfprx-will-announce-quarterly-sales-of-10-15-million.html.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Creative Planning boosted its position in Five Prime Therapeutics by 0.8% in the second quarter. Creative Planning now owns 6,744 shares of the biotechnology company’s stock valued at $203,000 after buying an additional 54 shares in the last quarter. Laurion Capital Management LP bought a new stake in Five Prime Therapeutics during the first quarter valued at about $210,000. Rockefeller Financial Services Inc. bought a new stake in Five Prime Therapeutics during the second quarter valued at about $210,000. BlueCrest Capital Management Ltd bought a new stake in Five Prime Therapeutics during the first quarter valued at about $254,000. Finally, Arxis Securities LLC bought a new stake in Five Prime Therapeutics during the first quarter valued at about $267,000. 85.10% of the stock is owned by institutional investors.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.